Cronos Group and Tilray were rallying Wednesday after analysts at Bank of America and Oppenheimer published bullish notes, respectively, on the cannabis companies. Cronos received a rare double upgrade from Bank of America analyst Christopher Carey, who upgraded the stock to buy from underperform while raising his price target to $20 from $13, representing a potential 39% upside.